We have advised international specialty pharmaceutical group Essential Pharma on its acquisition of the European rights to Colobreathe® from Teva Laboratories UK Limited.
With this transaction, Essential Pharma acquires the rights to Colobreathe® (colistimethate sodium) across European markets, including the UK. The deal represents Essential Pharma's first rare disease product acquisition. It further establishes the group as a leading specialty pharma business ensuring the continual supply of niche medicines of high clinical importance to patients, healthcare providers and carers.
Essential Pharma focuses on ensuring that patients have sustainable access to low volume, clinically well-established pharmaceutical products across key therapeutic areas. The group has been an important and valued partner to healthcare providers for over 20 years by giving patients access to medicines that otherwise might not be available. Essential Pharma operates globally in more than 70 countries, supplying a portfolio of over 300 products across multiple therapeutic areas.
Commenting on the transaction, private equity partner Suzy Davis said: "We are very pleased to have supported Essential Pharma with the legal advice to help them achieve this acquisition and expand their portfolio.”
The deal was led by partner Suzy Davis with support from Angela Petrevska in the Private Equity team. Further support was provided by partner Colin McCall and associate Alice Matthews in the Patents team, senior counsel Simon Jupp in the Technology, IP and Information team and partner Graham Samuel-Gibbon and associate Joe Fallon in the Tax and Incentives team.
